168
Participants
Start Date
August 28, 2020
Primary Completion Date
October 28, 2020
Study Completion Date
November 23, 2021
Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28
Two doses of middle-dose (20µg/ 0.5ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28.
Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28
Two doses of high-dose (40µg/ 1.0ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28.
Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28
Three doses of high-dose (40µg/ 1.0ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28
Two doses of placebo at the schedule of day 0, 28（middle-dose group）
Two doses of placebo (0.5ml) at the schedule of day 0, 28
Two doses of placebo at the schedule of day 0, 28（high-dose group）
Two doses of placebo (1.0ml) at the schedule of day 0, 28
Three doses of placebo at the schedule of day 0, 14, 28（high-dose group）
Three doses of placebo (1.0ml) at the schedule of day 0, 14, 28
Jiangsu Provincial Center for Diseases Control and Prevention, Nanjing
West China Hospital
OTHER
Jiangsu Province Centers for Disease Control and Prevention
NETWORK